Streit AK , Netter MF , Kempf F , Walecki M , Rinné S , Bollepalli MK , Preisig-Müller R , Renigunta V , Daut J , Baukrowitz T , Sansom MS , Stansfeld PJ , Decher N .

Wellcome Trust

	FIGURE 1. A1899 selectively blocks human TASK-1 channels expressed in Xenopus oocytes. A, human TASK-1 channels recorded with a voltage step protocol (200-ms steps from −70 mV to +70 mV with an increment of 10 mV; holding potential, −80 mV) before (left) and after (right) application of 40 nm A1899 (see inset for chemical structure of A1899). B, dose-response curve of A1899 on human TASK-1. Block was analyzed at the end of the test pulse to +40 mV. C, test for sensitivity of different potassium channels to 100 nm A1899 after heterologous expression in Xenopus oocytes. D, I-V relationships for TASK-1 in bath solution with high potassium concentration before (□) and after (■) application of 400 nm A1899. E, the percentage of inhibition by 400 nm A1899 from D plotted against the applied voltage. F, application of different concentrations of A1899 to TASK-3 channels recorded in intact whole oocytes (□) and in inside-out macropatches (○). The inset shows the recording of inside-out macropatches with a higher temporal resolution. TEVC, two-electrode voltage clamp.
	FIGURE 2. M2 and M4 segments of TASK-1 are part of the binding site for A1899. Four different chimeras, with TASK-4 transmembrane segments introduced into a TASK-1 background replacing M1, M2, M3, or M4, were analyzed for their IC50 of block by A1899. hTASK, human TASK.
	FIGURE 3. The HRE influences A1899 binding. A, the sequence of the HREs of TASK-1 and TASK-3 differ in one amino acid (VLRF(M/L)T) (indicated by a box). In both channels, in-frame deletion of the HRE (bottom) leads to a massive increase in IC50 values. rTASK, rat TASK. B, dose-response curves of A1899 on human TASK-1 WT (■) and an M247L (▴) mutant.
	FIGURE 4. The A1899 binding site includes residues of the M2 and M4 segment and the selectivity filter. A–F, mutant TASK-1 channels were expressed in Xenopus oocytes, and block by 400 nm A1899 was analyzed. A and D, sample current traces for wild-type TASK-1 and mutated channels before (black) and after (gray) application of 400 nm A1899. B, C, E, and F, mutant TASK-1 channels with a reduced sensitivity to A1899 indicate residues as part of the binding site for A1899 (illustrated as striated bars). Threonine residues of the P1 and P2 pore loops are part of the A1899 binding site. In the M2 and M4 segment, residues of the binding site are located at a distance of 3–4 amino acids.
	FIGURE 5. TASK-1 channels with multiple mutations at the drug binding site show a strong reduction of A1899 sensitivity. A, sample traces of TASK-1 wild-type, double, and triple mutant channels before (black) and after (gray) application of 400 nm A1899. B, inhibition of TASK-1 channels with multiple mutations by 400 nm A1899.
	FIGURE 6. Open-state pore homology model of TASK-1 based on the KvAP structure. The figure illustrates residues identified as pore-facing using A1899. For better display, the backbone of half a TASK-1 subunit (M1, P1 and M2) is hidden, whereas the identified residues are still depicted. The backbone is shown transparent for a better view on the residues of the drug binding site.
	FIGURE 7. Docking of A1899 to an open-state pore homology model of TASK-1. The binding mode of A1899 in the pore of TASK-1 as predicted by docking using the software GOLD is shown. All amino acids predicted to interact with the drug molecule are illustrated. For a better display of A1899 binding, the TASK-1 channel is shown in two orientations (rotated by 90°). The left panel shows the two M1, P1, and M2 segments, and the right panel shows the two M3, P2, and M4 segments. H-bonds are depicted as dotted lines between A1899 and the threonine residues of the selectivity filter.
	FIGURE 8. Molecular dynamics simulations validate the A1899 binding site. For a better display of A1899 binding, the TASK-1 channel is shown in two orientations (rotated by 90°). The left panel shows the two M1, P1, and M2 segments, and the right panel shows the two M3, P2, and M4 segments. All amino acids predicted to have multiple contacts with the drug molecule are illustrated. In addition, A1899 interacts with the potassium ion at S4 of the selectivity filter.

Armstrong, Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons. 1971, Pubmed

Armstrong, Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons. 1971, Pubmed
Ashmole, TASK-5, a novel member of the tandem pore K+ channel family. 2001, Pubmed , Xenbase
Barrows, Extracellular potassium dependency of block of HERG by quinidine and cisapride is primarily determined by the permeant ion and not by inactivation. 2009, Pubmed , Xenbase
Bruhova, Monte Carlo-energy minimization of correolide in the Kv1.3 channel: possible role of potassium ion in ligand-receptor interactions. 2007, Pubmed
Budde, Reciprocal modulation of I (h) and I (TASK) in thalamocortical relay neurons by halothane. 2008, Pubmed
Chatelain, The pore helix dipole has a minor role in inward rectifier channel function. 2005, Pubmed , Xenbase
Chen, Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. 2002, Pubmed , Xenbase
Czirják, TASK (TWIK-related acid-sensitive K+ channel) is expressed in glomerulosa cells of rat adrenal cortex and inhibited by angiotensin II. 2000, Pubmed , Xenbase
Decher, Characterization of TASK-4, a novel member of the pH-sensitive, two-pore domain potassium channel family. 2001, Pubmed , Xenbase
Decher, Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation. 2006, Pubmed , Xenbase
Dilmac, Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2. 2004, Pubmed
Doyle, The structure of the potassium channel: molecular basis of K+ conduction and selectivity. 1998, Pubmed
Duprat, TASK, a human background K+ channel to sense external pH variations near physiological pH. 1997, Pubmed , Xenbase
Faraldo-Gómez, Mechanism of intracellular block of the KcsA K+ channel by tetrabutylammonium: insights from X-ray crystallography, electrophysiology and replica-exchange molecular dynamics simulations. 2007, Pubmed
Kollewe, A structural model for K2P potassium channels based on 23 pairs of interacting sites and continuum electrostatics. 2009, Pubmed
Kuo, Crystal structure of the potassium channel KirBac1.1 in the closed state. 2003, Pubmed
Lerche, Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with a potassium ion in the selectivity filter. 2007, Pubmed , Xenbase
Long, Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment. 2007, Pubmed
Maingret, The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. 2001, Pubmed
Meadows, Functional characterisation of human TASK-3, an acid-sensitive two-pore domain potassium channel. 2001, Pubmed , Xenbase
Meuth, TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions. 2008, Pubmed
Mitcheson, A structural basis for drug-induced long QT syndrome. 2000, Pubmed , Xenbase
Patel, Inhalational anesthetics activate two-pore-domain background K+ channels. 1999, Pubmed
Putzke, The acid-sensitive potassium channel TASK-1 in rat cardiac muscle. 2007, Pubmed , Xenbase
Rajan, TASK-3, a novel tandem pore domain acid-sensitive K+ channel. An extracellular histiding as pH sensor. 2000, Pubmed , Xenbase
Reyes, Cloning and expression of a novel pH-sensitive two pore domain K+ channel from human kidney. 1998, Pubmed
Strutz-Seebohm, Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode. 2007, Pubmed
Trapp, A role for TASK-1 (KCNK3) channels in the chemosensory control of breathing. 2008, Pubmed
Treptow, The membrane-bound state of K2P potassium channels. 2010, Pubmed